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Current influenza vaccines generate humoral immunity, targeting highly variable epitopes 
and thus fail to achieve long-term protection. T cells recognize and respond to several 
highly conserved epitopes across influenza serotypes. A strategy of raising strong cyto-
toxic T cell memory responses to epitopes conserved across serotypes would provide 
cross serotype protection, eliminating the need for annual vaccination. We explored the 
adjuvant potential of epicutaneous (ec) and subcutaneous (sc) delivery of CpG oligode-
oxynucleotide in conjunction with sc protein immunization to improve protection against 
influenza A virus (IAV) infections using a mouse model. We found enhanced long-term 
protection with epicutaneous CpG ODN (ecCpG) compared to subcutaneous CpG
ODN (scCpG) as demonstrated by reduced viral titers in the lungs. This correlated with 
increased antigen-specific CD8 T cells in the airways and the lungs. The memory T cell 
response after immunization with ecCpG adjuvant was comparable to memory response 
by priming with IAV infection in the lungs. In addition, ecCpG was more efficient than 
scCpG in inducing the generation of IFN-γ producing CD4 T cells. The adjuvant effect 
of ecCpG was accompanied with its ability to modulate tissue-homing molecules on 
T cells that may direct them to the site of infection. Together, this work provides evidence 
for using ecCpG to induce strong antibody and memory T cell responses to confer 
protection against IAV infection.
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inTrODUcTiOn
Influenza virus belongs to the Orthomyxoviridae family of enveloped negative-sense, single-stranded 
segmented RNA viruses. Of the three subtypes of influenza viruses, influenza A virus (IAV) can infect 
many different species, including humans, other mammals, and birds. IAV is a highly contagious 
human respiratory pathogen and the cause of all influenza pandemics with a large impact on global 
health. Annual vaccination against seasonal influenza epidemics is recommended by governmental 
health organizations (1).
Abbreviations: BAL, broncheoalveolar lavage; CpG ODN, CpG oligo deoxynucleotide; ec, epicutaneous; ESL, E-selectin ligand; 
HAU, hemagglutinin units; IAV, influenza A virus; PSL, P-selectin ligand; sc, subcutaneous; Trm, tissue-resident memory T cells.
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Current inactivated influenza vaccines generate a strong anti-
body response that is moderately protective against the targeted 
IAV strains (2). However, they do not generate heterotypic immu-
nity that would be protective against a wide range of IAV strains, 
and only protect against the strains in the vaccine. Although 
current IAV vaccines can induce a strong humoral immune 
response, this response targets highly variable and rapidly chang-
ing epitopes on influenza hemagglutinin and neuraminidase (1). 
Thus, vaccination may offer little protection if the predominant 
IAV strains for the upcoming year are not well matched to the 
strains used in the vaccine (3). Furthermore, protection will 
wane over time as the prevailing IAV strains undergo genetic 
drift in the epitopes targeted by the vaccine (4). During the most 
recent IAV pandemic in 2009, the swine H1N1 strain infected 
an estimated 24% of the world’s population and was responsible 
for nearly 300,000 deaths (5, 6). The variable effectiveness of the 
seasonal IAV vaccines and the need to be immunized every year 
demonstrates the need for a universal IAV vaccine.
Although antibodies from B cells prevent the infection of 
cells by viruses, T cells are essential to eliminate infected cells. 
Cytotoxic CD8 T cells (CTLs) are responsible for the elimina-
tion of most IAV infected cells (7). Mice lacking CD8 T cells 
have a much higher mortality rate (8). T cells recognize highly 
conserved IAV epitopes; in humans, T cells respond to epitopes 
within the IAV proteins, M1 and nucleoprotein (9–11). These 
epitopes undergo little genetic drift and are highly conserved 
across IAV strains (12, 13). Indeed, CD8 T cells specific to con-
served viral epitopes were protective against symptomatic H1N1 
influenza in the absence of cross-reactive neutralizing antibodies 
(14). The low variability of influenza epitopes for cross-serotype 
T cell protection makes generation of a strong memory T cell 
response an attractive option for making a universal IAV vaccine. 
However, unlike neutralizing antibodies, memory T cells alone 
cannot completely block IAV infection (15). Thus, an ideal uni-
versal IAV vaccine should be capable of generating both a strong 
neutralizing antibody and a long-lived memory T cell response.
Vaccine efficacy is highly dependent on the route of delivery 
and its ability to properly stimulate the immune system (16). 
Optimizing the route of delivery and choice of adjuvant are essen-
tial for generating optimal quality and strength of the immune 
response. Adjuvants can be utilized to induce the desired type of 
immune response to a vaccine for protection. The two adjuvants 
currently approved in licensed vaccines in the United States are 
aluminum hydroxide (alum) and monophosphoryl lipid A. The 
mode of action of alum is not well understood but it appears to 
be independent of pattern recognition receptor signaling. Alum 
preferentially generates Th2-biased immune responses, while 
monophosphoryl lipid A is a TLR4 agonist that induces Th1-type 
immune responses (17–19). Finally, topical application of TLR7 
agonists at the time of influenza vaccination has been shown to 
improve antibody responses to influenza in the elderly (20).
The TLR9 agonist CpG oligodeoxynucleotide (ODN), mimics 
DNA patterns that are common in bacteria but rarely found in 
humans (21, 22). It has recently shown promising results as a novel 
adjuvant to boost immune responses and is currently in clinical 
trials as an adjuvant and immune modulator (23–25). Adjuvant 
CpG ODN enhances immune responses when co-administered 
with protein antigens. This was demonstrated for several 
clinically relevant pathogens, including Hepatitis B and anthrax 
(23–25). Importantly, CpG ODN stimulated both strong Th1 and 
B cell responses, which was similar to the immune response to 
IAV (26). CpG ODNs have recently been studied as IAV vaccine 
adjuvant in chicken (27), ducks (28), and murine models (29) 
delivered via the intramuscular, intradermal, and intranasal 
routes, respectively.
Delivering a vaccine at the site of natural infection is often 
effective at generating protective immunity. However, intranasal 
delivery of adjuvanted vaccine in a mouse model can result in 
the generation of detrimental Th17 cells (30). Thus, research into 
novel delivery routes to generate a safe, protective anti-IAV T cell 
response is warranted. Skin delivery of vaccines is a promising 
approach to generate protective immunity in many vaccination 
settings. Interestingly, although a primary immune response 
is initiated in the skin after viral skin infection, migratory and 
resident memory T cell populations are observed at diverse 
mucosal sites (31). These memory T cells are long-lived and 
are able to protect against reinfection at distal areas of the skin. 
Transcutaneous immunization against Chlamydia muridarum 
and Schistosoma mansoni elicited protective responses when 
challenged intravaginally or in the airways, respectively (32, 33). 
Importantly, these protective responses involve both humoral 
and cell-mediated contributions (34, 35).
The ability of adjuvant CpG ODN to help induce protective 
immune responses to vaccination through the skin is an active 
area of research. Addition of CpG ODN to Leishmania major vac-
cination induced strong and protective Th1 and Th17 responses 
(36). Topical adjuvant CpG ODN generated a robust antigen-
specific CTL response when administered with the OVA protein 
model antigen (37). Enhanced specific immune responses can 
protect against subsequent Listeria monocytogenes infection (38). 
Importantly, the route of application was critical for CpG ODN to 
optimally boost T cell responses. While intramuscular and sub-
cutaneous administration induced antigen-specific CD8 T cells, 
administration of CpG ODN by the transcutaneous route resulted 
in an enhanced CD8 T cell response that mediated protection.
As topical adjuvants can increase vaccine efficacy and promote 
T cell responses to vaccine antigen, we sought to harness immune 
cells in the skin to induce effective, long-lasting cellular immune 
responses, to potentially protect against different influenza sero-
types. We investigated whether CpG ODN applied topically to 
the skin at the time of subcutaneous protein vaccination could 
help drive a protective T cell response against IAV. We found that 
epicutaneous CpG ODN (ecCpG) drove both CD8 T  cell and 
antibody responses against IAV. These responses were sufficient to 
protect against subsequent IAV challenge in the lungs. Our work 
demonstrates the potential efficacy of immunization against IAV 
with adjuvant CpG ODN in the skin to drive a cross-protective 
T cell response that maybe relevant in influenza vaccine design.
MaTerials anD MeThODs
Mice
C57BL/6 mice were purchased from Charles River Laboratories 
(Wilmington, MA, USA). The B6.Cg-Tg (TcraTcrb) 425cbn/J 
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mice expressing a T cell receptor specific to OVA323–339 in the 
context of I-Ab (OT-II transgenic mice) and the B6.PL-Thy1a mice 
that carry the congenic Thy1.1 allele (Thy1.1 mice) were from 
The Jackson Laboratory (Bar Harbor, ME, USA). The Thy1.1 and 
the OT-II mice were crossed to generate Thy1.1+/+ OT-II+/+ mice. 
All mice were housed in a specific pathogen-free condition at the 
Child and Family Research Institute (Vancouver, BC, Canada) 
or at the Centre for Disease Modeling (Vancouver, Canada). 
Animal experiments were conducted in accordance with the 
protocols approved by the University Animal Care Committee 
and Canadian Council of Animal Care guidelines. Age-matched 
female mice were used between 6 and 12 weeks of age.
Viruses
The influenza strains used in this study are H1N1 A/Puerto 
Rico/8/34 (PR8) and H3N2 A/X-31, A/Aichi/68 (X31), and their 
derivatives PR8-OVA, and X31-OVA. PR8 is a mouse-adapted 
human IAV strain, while X31 is derived from the PR8 strain 
with its hemagglutinin and neuraminidase genes replaced by 
those from H3N2 A/Hong Kong/1/1968 (39). The PR8-OVA 
and X31-OVA strains contain the CD8 T cell epitope SIINFEKL 
(OVA257–264) in the neuraminidase stalk (40). PR8 and X31 were 
purchased from Charles River Laboratories (Wilmington, MA, 
USA). PR8-OVA and X31-OVA were grown in-house as previ-
ously described (41).
Deoxynucleotides
Synthetic HPLC-purified, single-stranded, phosphorothiolated 
CpG ODN 1826 (5′-TCCATGACGTTCCTGACGTT-3′) was 
purchased from Sigma-Aldrich Inc. (Saint Louis, MO, USA). 
Lyophilized CpG ODN 1826 was reconstituted to 5 mg/mL with 
PBS/DMSO (1:1 v/v).
immunization
Mice were immunized as previously described (42). Mice were 
anesthetized by intraperitoneal injection of 75 mg/kg ketamine 
(ketalean, Bimeda-MTC Animal Health Inc., Cambridge, ON, 
Canada) and 7.5  mg/kg xylazine (Rompun, Bayer Health Care 
Inc., Toronto, ON, USA). The backs of the mice were then 
shaved, tape-stripped 15 times using cellophane tape (Staples, 
Vancouver, BC, Canada). The exposed skin was gently rubbed 
with acetone (Fisher Scientific, Edmonton, AB, Canada) using 
a cotton swab. One hundred micrograms of chicken ovalbumin 
antigen (OVA, Grade V, Sigma) in PBS were injected subcutane-
ously. CpG ODN in PBS/DMSO as adjuvant was administered 
either epicutaneously (250 μg, epifocal to the antigen injection 
site on a 1  cm ×  1  cm 1-ply paper towel) or co-injected with 
OVA subcutaneously (50  μg). For experiments examining the 
IAV antibody response, PR8 was heat-inactivated for 2 h at 56oC 
before administered with CpG ODN as above. The immunization 
site was protected with water-resistant tape (Transpore 3  M) 
overnight. For a prime-boost immunization schedule, mice were 
immunized twice, 7 days apart.
influenza a infection
For immunizing infection, mice were anesthetized using iso-
flurane and infected twice intranasally with 10  hemagglutinin 
units (HAU) of X31 or 20 HAU of X31-OVA in 25 μL of sterile 
PBS, 7 days apart. To challenge the immunized mice, mice were 
infected intranasally with 5 HAU of PR8 or 10 HAU of PR8-OVA 
in 25 μL of sterile PBS at 5 or 30 days after the booster or primary 
infection.
Plaque assays
Plaque assays were performed as previously described (43). Three 
days after infection with PR8-OVA lungs from infected mice were 
homogenized using a Fisher Tissuemiser, diluted in PBS and 
incubated on at least 80% confluent MDCK cells (ATCC) for 1 h 
at room temperature (RT). The wells were rinsed with PBS and 
a solution of 0.7% agarose, 0.1% trypsin in α-MEM was applied 
and allowed to solidify. Samples were then incubated at 37°C for 
4 days before staining with crystal violet and counting of plaques.
adoptive Transfer of T cells
Single cell suspension was prepared from lymph nodes (cervical, 
axillary, brachial, pancreatic, inguinal, and mesenteric) and the 
spleen of Thy1.1 OT-II mice by forcing through a 40 μm filter. 
Single cell suspension was enriched for CD4 T cells (>85% 
purity) by negative selection using EasySep™ Mouse CD4 T 
Cell Enrichment Kit (STEMCELL Technologies Inc., Vancouver, 
BC, Canada). 2 × 106 cells were adoptively transferred via lateral 
tail vein injection 1 day before the experiment.
cell Preparation and Flow cytometry
Broncheoalveolar lavage (BAL) fluid was obtained by inserting 
a tracheal catheter and washing the bronchoalveolar space four 
times with 1 mL of PBS supplemented with 10% FBS. Lymphocytes 
were extracted from the lungs of mice by mincing with scissors, 
digesting with 100 units/mL collagenase IV for 1 h at 37°C before 
filtering through a 70  μm filter to remove debris. Single cell 
suspension of spleens and skin draining lymph nodes (axillary 
and brachial) were prepared as described above. Erythrocytes 
in spleen were lysed with ACK lysis buffer before proceeding to 
staining.
Antibodies were purchased from BD Bioscience (San Diego, 
CA, USA), eBioscience (San Diego, CA, USA) and BioLegend (San 
Diego, CA, USA). H2-Kb OVA257–264 tetramer labeled with PE was 
made in-house by Dr. Rusung Tan’s Laboratory (Child and Family 
Research Institute, Vancouver, BC, Canada). H2-Kb NP366–374 and 
PA224–233 tetramers labeled with PE and APC, respectively, were 
made by the NIH Tetramer Core Facility (Atlanta, GA, USA). 
Purified mouse P-selectin–Ig fusion protein was purchased from 
BD Bioscience (San Diego, CA, USA) and the recombinant mouse 
E-selectin Fc chimera was from R & D Systems Inc. (Minneapolis, 
MN, USA).
Tetramer staining was carried out at RT for 30 min before anti-
body staining at 4°C for 30 min. For intracellular IFN-γ staining, 
cells were restimulated with PMA and ionomycin ex vivo at 37°C 
for 4 h before surface markers staining at 4°C for 30 min. Cells 
were fixed and permeabilized with Fixation and Permeabilization 
buffer from eBioscience and then stained for intracellular IFN-γ 
at RT for 30 min. Data were acquired on a LSRII flow cytometer 
using FACSDiva software (BD Bioscience) and analyzed using 
FlowJo software (TreeStar, Stanford, CA, USA).
FigUre 1 | epicutaneous cpg ODn adjuvantation at the time of 
immunization protects against flu infection. C57BL/6 mice 
immunized with (a) scOVA ± ecCpG ODN or (B) scOVA + sc or ecCpG 
ODN were infected with PR8-OVA virus intranasally 5 or 30 days post-
immunization. Three days post-infection, lung homogenates were 
analyzed for plaque forming units. Bar graphs represent mean ± SD from 
two independent experiments (n = 9–11). Statistical significance 
comparing the immunized groups was analyzed by non-parametric 
two-tailed Mann–Whitney test *p < 0.05.
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Detection of antigen-specific 
antibodies by elisa
Nunc 96-well Flat Bottom Immuno Plates were coated with 
2 μg of OVA protein (Sigma) in 100 μL of 50 mM bicarbonate/
carbonate buffer, pH 9.6 buffer, or 500 HAU/mL of inactivated 
PR8 per well. For OVA-specific antibodies, plates were blocked 
with 2% bovine serum albumin (BSA) in PBS at 37°C for 1  h. 
Twofold serial dilutions of sera were incubated on the plates at 
RT for 2 h and bound antibodies were detected with horserad-
ish peroxidase (HRP)-linked Goat Anti-Mouse IgG and IgG2c 
antibody from Jackson ImmunoResearch (West Grove, PA, USA). 
Plates were washed between each step with 0.05% Tween in PBS. 
Tetramethylbenzidine substrate was added for signal detection 
and the reaction was stopped with 2N sulfuric acid. Absorbance 
was measured at 450 nm. For influenza-specific antibodies, plates 
coated overnight at 4°C with heat-inactivated IAV and were blocked 
with 1% BSA and 0.1% Tween in PBS at RT for 1 h. Fivefold serial 
dilutions of sera were incubated on the plates at 4°C overnight 
and bound antibodies were detected with biotin-conjugated anti-
mouse IgG2b at 37°C for 2 h and avidin-HRP in blocking buffer at 
RT for 45 min. Substrate 2,2′-azino-bis(3-ethylbenzothiazoline-
6-sulphoic acid) was added and the reaction was stopped with 2N 
sulfuric acid. Absorbance was measured at 490 nm.
statistical analysis
Data are presented as mean ± SEM and analyzed by Student’s t-test 
or one-way ANOVA with Tukey’s post-test as appropriate. Results 
giving a p-value of less than 0.05 were considered significant.
resUlTs
cpg ODn adjuvant enhances Protection 
from influenza a Virus challenge
To assess the ability of ecCpG adjuvant to provide protection from 
intranasal IAV infection, naive C57BL/6 mice or mice immunized 
with the OVA antigen subcutaneously (scOVA) or scOVA with 
ecCpG adjuvant were challenged with PR8-OVA 5 or 30  days 
post-immunization. At 3 days post-infection, lung homogenates 
from challenged mice were analyzed by plaque assay to assess 
viral loads. The number of plaques was significantly lower in the 
ecCpG adjuvanted mice compared to mice given scOVA alone. 
This difference was seen in mice that were challenged 5 or 30 days 
post-immunization (Figure 1A).
Since ecCpG adjuvant was superior to subcutaneous CpG ODN 
(scCpG) adjuvant in providing protective immunity to L. mono-
cytogenes (38), we further assessed whether ecCpG adjuvant is 
superior to scCpG adjuvant in providing protection from IAV. 
Mice were immunized with either scOVA and scCpG, or scOVA 
and ecCpG. Mice were challenged with PR8-OVA either 5 or 
30 days post-immunization and lungs were harvested for plaque 
assays 3  days later. Interestingly, significantly lower number of 
plaques was detected in the lung homogenates from mice given 
CpG adjuvant epicutaneously compared to subcutaneously at day 
30 post-infection (Figure 1B). These results show that adminis-
tering CpG ODN adjuvant epicutaneously reduces viral load in 
the lungs, which suggests a protective effect of the immunization. 
In addition, ecCpG compared to scCpG adjuvant is more effective 
after 30 days in enhancing protection against IAV challenge.
epicutaneous cpg ODn adjuvant 
Drives Memory cD8 T cell response 
in the lungs
Memory CD8 T cells recognize conserved proteins, including 
nucleoprotein from different subtypes of IAV and, thus, may 
be harnessed to broaden protection against the virus (44). 
We speculated that memory CD8 T cells contributed to the 
protection from IAV infection driven by scOVA  +  ecCpG 
immunization. Therefore, we investigated the ability of ecCpG 
adjuvant to drive the memory CD8 T cell response. Mice were 
restimulated 100 days after immunization with scOVA at the site 
of primary immunization and the proportions of OVA-specific 
CD8 T cells in different sites were analyzed by flow cytometry. 
The total number of OVA-specific CD8 T cells in the lungs and 
the spleen were also enumerated. Immunization with CpG ODN 
adjuvant increased the percentage of OVA-specific CD8 T cells in 
the spleen and the lungs (Figures 2A,B). This increase in OVA-
specific CD8 T cells in the organs of ecCpG adjuvanted mice 
was also manifested in absolute cell numbers (Figure 2C). These 
FigUre 2 | epicutaneous cpg ODn induces long-term cTl memory. 
C57BL/6 mice immunized with scOVA ± ecCpG or scCpG ODN were 
restimulated with scOVA antigen at the same site of immunization 100 days 
post-immunization. Lungs and spleen were collected for flow cytometric 
analysis and OVA-specific CD8 T cells were enumerated. (a) Representative 
flow cytometric plots of the B220−CD8+ population, gating for OVA tetramer 
and CD8 double-positive cells. (B) The percentage and (c) total number of 
OVA-specific tetramer+ cells among CD8+ T cells in the lungs and spleen. Bar 
graphs show the mean ± SD from two independent experiments (n = 4–6). 
Statistical significance of all four groups was analyzed by one-way ANOVA 
test with a Tukey’s multiple comparison post hoc analysis *p < 0.05.
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data indicate that one mechanism by which adjuvant ecCpG 
drives memory CD8 T cell response is to increase the number 
of antigen-specific CD8 T  cells whereby ecCpG is superior to 
scCpG adjuvant in doing so. Intriguingly, ecCpG and scCpG 
drove specific CD8 T cells both in the lymphoid organs and at 
a distant site from where the antigen was re-introduced.
epicutaneous cpg ODn adjuvant 
Promotes strong Memory cD8 T cell 
response at the site of influenza a Viral 
infection
Given the increase in antigen-specific CD8 memory T cells after 
immunization with ecCpG adjuvant and reintroduction of the 
antigen, we next investigated the generation of memory T cells 
upon re-challenge of immunized mice with live IAV. PR8 IAV or 
virus expressing an OVA epitope recognized by CD8 T cells (PR8-
OVA) was used to challenge the mice 30 days post-immunization 
to examine antigen-specific responses. The less virulent IAV, X31, 
and its derivative that express the CD8 T cell epitope of OVA 
(X31-OVA) were used to infect the mice. Mice were then chal-
lenged with PR8 and PR8-OVA as negative and positive controls, 
respectively, for memory OVA-specific CD8 T cell generation. 
Three days after challenge, we examined the response in the 
lungs, spleen, and BAL, which samples the epithelial lining 
of the pulmonary airways. Significantly higher percentages of 
OVA-specific CD8 T cells were detected in ecCpG adjuvanted 
mice compared to mice immunized with antigen alone in all the 
compartments analyzed (Figures 3A,B). The memory response 
in the lungs was comparable between mice immunized with 
scOVA +  ecCpG and mice infected with X31-OVA upon chal-
lenging with PR8-OVA. Increased numbers of OVA-specific CD8 
T cells were detected in the lungs and spleen of mice immunized 
with scOVA +  ecCpG compared to scOVA alone. Importantly, 
equivalent numbers of OVA-specific CD8 T cells were detected 
in the lungs of scOVA + ecCpG immunized mice compared to 
X31-OVA infected mice (Figure 3C). These results confirm the 
ability of ecCpG adjuvant to induce memory antigen-specific 
CD8 T cell response in the lungs. Using ecCpG as an adjuvant 
can effectively enhance memory CD8 T cell response at the sites 
of IAV infection, including the airways and the lungs, which were 
as strong as that generated by primary IAV infection.
epicutaneous cpg adjuvant stimulates a 
strong humoral response
Antibody responses remain a standard method to evaluate vac-
cines and are essential in long-term protective immunity. Mice 
were immunized using a prime-boost schedule with scOVA, 
scOVA  +  scCpG, or scOVA  +  ecCpG. The relative titers of 
OVA-specific total IgG and IgG2c antibodies in the serum were 
measured 30 days post-immunization (Figure 4A). Independent 
of the route of administration, CpG ODN adjuvant increased the 
amount of total IgG and IgG2c relative to immunization without 
adjuvant. To mimic influenza vaccines, we also measured relative 
antibody titers in mice subcutaneously immunized with heat-
killed PR8 (scHKI). As speculated, increased IgG2b antibodies 
were detected with CpG ODN adjuvant regardless of the route of 
delivery compared to antigen alone (Figure 4B).
epicutaneous cpg adjuvant stimulates a 
strong Th1 response from cD4 T cells
CD4 T cells not only provide help to B cell clonal expansion 
and antibody production (45), they also play important roles in 
FigUre 4 | epicutaneous cpg ODn enhances antibody responses to 
influenza virus. C57BL/6 mice immunized with scOVA ± ecCpG or scCpG 
ODN, or subcutaneously with heat-killed IAV (scHKI) ± ecCpG or scCpG 
ODN. Sera were collected 30 days post-immunization and serial diluted. 
Relative levels of (a) OVA-specific total IgG, IgG2c, and (B) IgG2b antibodies 
in serum from the different groups of mice were measured by ELISA. Line 
graphs show the mean ± SD of antibody levels from two independent 
experiments (n = 6).
FigUre 3 | epicutaneous cpg ODn induces memory cTl responses 
equivalent to primary influenza viral infection. C57BL/6 mice immunized 
with scOVA ± ecCpG ODN or intranasally infected with X31-OVA virus were 
challenged with PR8-OVA virus 30 days post-immunization. The BAL, lungs, 
and spleen were collected 3 days post-challenge for flow cytometric analysis 
and OVA-specific CD8 T cells were enumerated. (a) Representative flow 
cytometric plots of the B220−CD8+ population, gating for OVA tetramer+ 
CD8+ double-positive cells. (B) The percentage and (c) total number of 
OVA-specific cells among CD8+ T cells in the BAL, lungs, and spleen, 
including the negative controls of mice immunized with X31 and challenged 
with PR8. Bar graphs are showing the mean ± SD from a representative 
experiment from three independent experiments (n = 3–6). Statistical 
significance of all four groups was analyzed by one-way ANOVA test with a 
Tukey’s multiple comparison post hoc analysis. *p < 0.05.
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the development and maintenance of functional CD8 memory 
T cells (46, 47). The CD4 Th1 cell subset is characterized by 
the production of IFN-γ. There is evidence that IFN-γ can act 
directly on CD8 T cells to increase their number during acute 
viral infection (48). The OT-II adoptive transfer system was used 
to examine the effect of ecCpG adjuvant on CD4 T cells. Mice 
were first adoptively transferred with CD4 T cells from OT-II 
T cell receptor transgenic mice carrying the Thy1.1 congenic 
allele, then immunized with scOVA alone, scOVA + scCpG, or 
scOVA + ecCpG. After 3 days, cells were isolated from the spleen 
and skin draining lymph nodes and restimulated with PMA 
and ionomycin ex vivo. Although there was no difference in the 
number of Thy1.1 OT-II cells, intracellular cytokine staining 
showed a fourfold increase in the proportion of IFN-γ-producing 
Thy1.1 OT-II cells in the lymphoid organs with scOVA + scCpG 
immunization compared to scOVA alone (Figures 5A,B). When 
mice were immunized with scOVA +  ecCpG, we observed an 
increase in IFN-γ-producing Thy1.1 OT-II cells in the skin drain-
ing lymph nodes and the spleen compared to scOVA +  scCpG 
immunization (Figures  5A,B). Similarly, the total number of 
IFN-γ-producing Thy1.1 OT-II cells were also significantly 
increased in the skin draining lymph nodes and the spleen with 
ecCpG adjuvant (Figure 5C). These results suggest that ecCpG 
is superior to scCpG adjuvant in stimulating IFN-γ production 
from antigen-specific CD4 T cells.
FigUre 5 | epicutaneous cpg ODn enhances Th1 responses. 
C57BL/6 mice adoptively transferred with CD4+ Thy1.1+ OT-II T cells were 
immunized with scOVA ± ecCpG or scCpG ODN. Skin draining lymph nodes 
and spleen were collected 3 days after and cells were restimulated with PMA 
and ionomycin ex vivo for 4 h. Cells producing IFN-γ were detected by 
intracellular IFN-γ staining and flow cytometric analysis. (a) Representative 
flow cytometric plots of CD4+ and Thy1.1+ cells, gating for CD4 IFN-γ double-
positive cells is shown. (B) The percentage of IFN-γ producing cells among 
CD4+ Thy1.1+ OT-II T cells in the skin draining lymph nodes and spleen. 
(c) Total number of IFN-γ producing CD4+ Thy1.1+ OT-II T cells in the skin 
draining lymph nodes and spleen. Bar graphs are showing the mean ± SD 
from a representative experiment from three independent experiments 
(n = 3–4). Statistical significance of all four groups was analyzed by one-way 
ANOVA test with a Tukey’s multiple comparison post hoc analysis. *p < 0.05.
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epicutaneous cpg adjuvant Modulates 
homing Molecules on cD4 T cells
Immunization with ecCpG adjuvant drove memory CD8 T cell 
response in the lungs upon intranasal influenza viral infection 
(Figure 3). P-selectin ligand (PSL) and E-selectin ligand (ESL) 
are molecules required for the transmigration of T cells from 
the endothelium to blood into lymphoid organs (49). Moreover, 
P-selectin binds only to antigen-specific T cells in draining 
lymph nodes after immunization (50). It has been shown that 
independent of the route of herpes simplex viral infection, CD8 
central memory T cells expressed substantial levels of the ESL 
and PSL during both the effector and memory phase of the 
response. By contrast, epicutaneous infection led to significantly 
higher expression of tissue-homing molecules in CD4 helper T 
cells (51). CD4 T cells affect the outcome of CD8 responses, by 
enhancing clonal expansion, facilitating the entry of effectors into 
inflamed tissues, and promoting the survival of memory cells, 
all of which are preceded by the tuning of antigen-presenting 
cells in lymph nodes by the CD4 cells (52). We hypothesized that 
ecCpG adjuvant with subcutaneous protein antigen upregulates 
the expression of tissue-homing molecules on antigen-specific 
T cells. Using a CD4 OT-II transgenic T cell adoptive transfer 
approach, we investigated the expression of tissue-homing mol-
ecules on antigen-specific cells after immunization. Mice were 
adoptively transferred with Thy1.1 OT-II transgenic T cells and 
then immunized the next day with scOVA, scOVA + scCpG, or 
scOVA + ecCpG. The skin draining lymph nodes were analyzed 
3 days post-immunization. Epicutaneous delivery of CpG ODN 
adjuvant increased the proportion of OT-II cells expressing PSL 
and ESL compared to scCpG delivery (Figure  6). By contrast, 
the proportion of the OT-II cells expressing L-selectin (CD62L) 
was decreased. These data are consistent with the hypothesis that 
ecCpG adjuvant promotes expression of the homing molecules of 
PSL and ESL. In addition, the ecCpG adjuvant reduces expression 
of lymph node homing molecule CD62L.
DiscUssiOn
The route of vaccination and the adjuvant applied governs the 
immune responses to vaccination with protein antigens. Thus, 
developing a universal IAV vaccine involves the investigation of 
the optimal delivery of the vaccine. Cutaneous immunization is 
able to generate protective resident memory T cell populations at 
distal mucosal sites in various infection and vaccination settings 
(53). In addition, the TLR9 agonist CpG ODN preferentially 
induces a strong CD4 Th1 and CD8 immune response (54). 
During the 2009 H1N1 pandemic, prior elevated frequencies 
of influenza-specific CD8 T cells correlated with protection 
against symptomatic disease (14). The induction of a strong, CTL 
response may, thus, confer broader and more persistent protec-
tion from IAV infection as the epitopes recognized by CD8 T cells 
are more conserved.
In this study, we investigated whether the combination of 
subcutaneous protein immunization with ecCpG adjuvant could 
induce protective memory T cell responses to IAV. Our immuni-
zation and challenge system allowed us to specifically examine 
protection driven by memory CD8 T cells. This was accomplished 
FigUre 6 | epicutaneous cpg ODn enhances P- and e-selectin 
ligand expression in cD4 antigen-specific T cells. C57BL/6 mice 
adoptively transferred with CD4+ Thy1.1+ OT-II T cells were immunized with 
scOVA ± ecCpG ODN. Skin draining lymph nodes were collected for flow 
cytometric analysis 3 days post-immunization. (a) Representative flow 
cytometric plots of CD4 Thy1.1 double-positive cells showing selectin ligand 
expression. (B) The percentage of single-positive cells for CD62L, PSL, or 
ESL among CD4+ Thy1.1+ cells in the skin draining lymph nodes. Bar graphs 
show the mean ± SD of 4 individual experiments, n = 9. Statistical 
significance of all three groups was analyzed by one-way ANOVA test with a 
Tukey’s multiple comparison post hoc analysis. *p < 0.05.
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since we immunized and boosted with the whole ovalbumin pro-
tein plus CpG ODN as the adjuvant. However, challenge of the 
immunized mice was done with the PR8-OVA virus, with only 
the MHC-I restricted ovalbumin epitope, SIINFEKL, as the com-
mon antigen between immunization and challenge. We showed 
that CpG ODN as an adjuvant generated a protective CD8 T cell 
response to IAV challenge, and that route of delivery was critical 
for optimal response and protection. While CpG ODN delivered 
subcutaneously with antigen was able to generate a memory CD8 
T cell response, only epicutaneous delivery generated a robust 
CD8 T cell response that conferred protection against IAV infec-
tion. This suggests that epicutaneous application of CpG ODN 
adjuvant is superior to subcutaneous administration.
After an infection, memory T cells form distinct populations 
of tissue resident and migratory cells. There are three major 
subsets of memory T cells: central memory, effector memory, 
and tissue resident memory T cells (55, 56). Central memory 
T cells are CD127+ CD62L+, have a higher proliferative potential 
than naive cells, and preferentially reside in lymphoid organs. 
Effector memory T cells are CD127+ CD62L−, have a faster effec-
tor response, and preferentially reside in non-lymphoid (stromal) 
tissues. Unlike central memory T cells, Trm permanently reside 
in their home tissue and do not recirculate into the blood (31). 
Trm are conditioned by the tissue environment in which they 
arise (57). Transferring Trm cells to a naïve animal will result 
in nearly all of them returning to the imprinted tissue (58). 
Interestingly, memory cells generated in the skin are able to home 
to multiple tissues (59). The mechanism by which the skin can 
program T cells to home to other sites has not been determined. 
By contrast, central memory T cells patrol lymph nodes and tis-
sues for antigen but do not permanently reside in the tissues or 
have any tissue-specific conditioning (58). While both of these 
populations confer protection against reinfection, Trm cells tend 
to be more effective (56). Their location proximal to the site of 
infection enables them to respond rapidly to reinfection and they 
are able to efficiently recruit help from the innate immune sys-
tem and the circulating memory T cell populations. Our results 
demonstrated that immunization with ovalbumin and ecCpG 
adjuvant was effective at generating a protective secondary CD8 
T cell response to PR8-OVA infection in the lungs and the BAL 
fluid. Although the nature of the memory CD8 population gener-
ated upon immunization with scOVA + ecCpG is still undefined, 
these cells responded equally well to IAV reinfection as memory 
CD8 T cells generated by a primary IAV infection and are consist-
ent with the presence of a Trm population.
The peripheral response to re-challenge with PR8-OVA was 
quantitatively different between mice vaccinated with scOVA +  
ecCpG and infected with X31-OVA. The secondary T cell response 
in X31-OVA primed mice was confined to the BAL and the lungs. 
This is typical of a memory T cell response to IAV. However, in mice 
vaccinated with scOVA + ecCpG, we detected a strong CD8 T cell 
response in the spleen, unlike mice that were initially infected 
with IAV. This indicated that skin vaccination might have induced 
a larger circulating memory CD8 T cell population than primary 
IAV infection, leading to an enhanced secondary response. The 
implications of an enhanced peripheral CD8 T cell response to 
IAV re-challenge include enhanced  vaccine efficacy; an outcome 
that will need to be clinically tested.
While memory CD8 T cell responses have the potential to 
provide cross-serotype immunity against IAV, they cannot com-
pletely prevent reinfection like protective humoral immunity (1). 
In addition to generating a protective CD8 T cell response, CpG 
ODN adjuvant enhanced the production of antigen-specific IgG 
antibodies, independent of the route of administration. When 
we examined the CD4 T cell population, we found that ecCpG 
was superior to scCpG ODN adjuvant in generating the IFN-γ-
producing Th1 cells. Although the role of CD4 T cells in protec-
tion from IAV infection is still debated, they are recognized to 
contribute to the clearance of IAV (60). Taken together, it remains 
beneficial to elicit a humoral response against influenza strains in 
addition to the induction of CD8 T cell memory.
The development of the adaptive immune response is influ-
enced by innate immune cells and their context of activation. 
The skin is spatially segregated into layers with different stromal 
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and immune cell types in each layer. Thus, there is both func-
tional and spatial separation of the immune response between 
cells. The difference in response between mice treated with 
scCpG versus ecCpG adjuvant demonstrates the importance 
of separation of function in immune priming. It is important 
to dissect the effects of treatments to different layers in modu-
lating the local immune response. In this setting, stimulation 
of the epidermis was critical for the generation of protective 
CD8 T cell memory. ecCpG enabled the cross-presentation of 
soluble protein antigen-specific CD8 T cells administered either 
intramuscularly or subcutaneously (42). The main cell types 
in the epidermis that express TLR9 and recognize CpG ODN 
are keratinocytes and Langerhans cells (LCs). Langerhans cells 
activated by CpG ODN are able to migrate to draining lymph 
nodes and cross-present antigen to CD8 T cells (42). Stimulation 
of keratinocytes through TLR9 triggers the production and 
release of cytokines and chemokines, such as TNF-α, IL-1α, and 
type I interferons (61). Furthermore, cytokines and chemokines 
released by keratinocytes after stimulation by CpG ODN 
enhance the ability of LCs to cross-present and activate CD8 T 
cells (62). It is likely that CpG ODN stimulation of keratinocytes, 
LCs, or both was essential for priming of CD8 T cells in the skin 
to a memory population that protected against IAV challenge 
in the lungs.
It is important for vaccines to generate both memory B and 
T cells to provide long-term protection. Higher frequencies of 
antigen-specific memory T cells correlate with enhanced protec-
tion (63, 64). Due to their higher activation state, memory T cells 
respond to pathogen encountered in a faster and stronger manner 
in subsequent exposures (65). CD4 T cells help direct and tune 
CD8 T cell responses. We investigated the effect of immunization 
with ecCpG compared to scCpG adjuvant in modulating selectin 
expression that would correlate with the homing potential of 
antigen-specific CD4 T cells. Results from our study supports 
the hypothesis that ecCpG adjuvant promotes the expression of 
tissue-homing molecules on memory T cells, including PSL and 
ESL that was not detected with subcutaneous delivery of the 
adjuvant. By contrast, the expression of lymph node-retaining 
molecule CD62L was decreased with epicutaneous delivery of 
CpG ODN adjuvant but not with subcutaneous delivery. This 
effector memory T cells pattern of adhesion molecules may allow 
memory T cells to migrate peripheral tissues and to mount a 
strong response against IAV to provide the first line of defense 
at the site of infection.
Vaccination is one of the most effective public health interven-
tions in use today. Transcutaneous immunization is a promising 
delivery route for the development of new and improved vaccines 
and adjuvants. We have demonstrated that standard subcutane-
ous protein vaccination with ecCpG ODN adjuvant generated a 
strong memory CD8 T cell response that conferred protection 
from IAV challenge in the lungs. The combination of delivery 
route and adjuvant was important for an effective memory CD8 
T cell response and may be applicable to other vaccine settings. 
Results from this study can guide future endeavors in under-
standing the mechanism of ecCpG ODN adjuvant enhancement 
of the efficacy of IAV and other vaccines to induce both protective 
T cell and humoral response.
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